1-14 of 14
Prakash Mistry
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 1276: Identification of S65487/VOB560 as a potent and selective intravenous 2nd-generation BCL-2 inhibitor active in wild-type and clinical mutants resistant to Venetoclax

Arnaud Le Tiran, Audrey Claperon, James Davidson, Jérôme-Benoit Starck, Thierry Le Diguarher, Maïa Chanrion, Prakash Mistry, Youzhen Wang, Elodie Monceau, Fabienne Bernhardt, Francesca Rocchetti, Gaelle Lysiak-Auvity, Ijen Chen, Zoe Daniels, Chris Pedder, Mandy Fallowfield, Jean-Michel Henlin, Imre Fejes, Janos Tatai, Miklos Nyerges, Didier Durand, Marion Zarka, Sneha Sanghavi, Anne-Marie Girard, Marie Schoumacher, Laurence Kraus-Berthier, Rick Newcombe, Ensar Halilovic, Sébastien Banquet, Alain Rupin, Heiko Maacke, James Murray, Erick Morris, Francesco Hofmann, Frédéric Colland, Olivier Geneste
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1276.
https://doi.org/10.1158/1538-7445.AM2021-1276
Published: 01 July 2021
View article titled, Abstract 1276: Identification of S65487/VOB560 as a potent and selective intravenous 2<sup>nd-</sup>generation BCL-2 inhibitor active in wild-type and clinical mutants resistant to Venetoclax
Journal Articles

Abstract 4482: S64315 (MIK665) is a potent and selective Mcl1 inhibitor with strong antitumor activity across a diverse range of hematologic tumor models

Ana Leticia Maragno, Prakash Mistry, András Kotschy, Zoltán Szlavik, James Murray, James Davidson, Gaëtane Le Toumelin-Braizat, Maïa Chanrion, Alain Bruno, Audrey Claperon, Heiko Maacke, Erick Morris, Youzhen Wang, Alix Derreal, Márton Csekei, Attila Paczal, Zoltán Szabo, Szabolcs Sipos, Agnes Proszenyak, Balázs Balint, Allan Surgenor, Pawel Dokurno, Natalia Matassova, Ijen Chen, Gaëlle Lysiak-Auvity, Anne-Marie Girard, Fabienne Grave, Frédéric Colland, Ensar Halilovic, Olivier Geneste
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 4482.
https://doi.org/10.1158/1538-7445.AM2019-4482
Published: 01 July 2019
View article titled, Abstract 4482: S64315 (MIK665) is a potent and selective Mcl1 inhibitor with strong antitumor activity across a diverse range of hematologic tumor models
Journal Articles

Abstract 4477: MIK665/S64315, a novel Mcl-1 inhibitor, in combination with Bcl-2 inhibitors exhibits strong synergistic antitumor activity in a range of hematologic malignancies

Ensar Halilovic, Maïa Chanrion, Prakash Mistry, Markus Wartmann, Shumei Qiu, Sneha Sanghavi, Yan Chen, Gaëlle Lysiak, Ana Leticia Maragno, Ulrike Pfaar, Felix Huth, Marie Schoumacher, Audrey Claperon, Laurence Kraus-Berthier, Sébastien Banquet, Alix Derreal, Heiko Maacke, Frédéric Colland, Olivier Geneste, Erick Morris, Youzhen Wang
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 4477.
https://doi.org/10.1158/1538-7445.AM2019-4477
Published: 01 July 2019
View article titled, Abstract 4477: MIK665/S64315, a novel Mcl-1 inhibitor, in combination with Bcl-2 inhibitors exhibits strong synergistic antitumor activity in a range of hematologic malignancies
Journal Articles

Abstract 257: Targeting AML through apoptosis activation using Bcl-2/Mcl-1 or Bcl-2/Hdm2 inhibitor combination therapies

Youzhen Wang, Shumei Qui, Sneha Sanghavi, Iain Mulford, Gaëlle Lysiak, Maïa Chanrion, Prakash Mistry, Ulrike Pfaar, Marie Schoumacher, Audrey Claperon, Laurence Kraus-Berthier, Sébastien Banquet, Alix Derreal, Claire Fabre, Heiko Maacke, Frédéric Colland, Olivier Geneste, Erick Morris, Ensar Halilovic
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 257.
https://doi.org/10.1158/1538-7445.AM2019-257
Published: 01 July 2019
View article titled, Abstract 257: Targeting AML through apoptosis activation using Bcl-2/Mcl-1 or Bcl-2/Hdm2 inhibitor combination therapies
Journal Articles

Abstract 3370: Use of fine needle aspirate biopsy (FNAB) in evaluating drug responses in tumor models: Better data with less animal use? .

Christian R. Schnell, Prakash Mistry, Julien Perdoux, Robert Cozens, Matthew Meyer, Tinya Abrams
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 3370.
https://doi.org/10.1158/1538-7445.AM2013-3370
Published: 15 April 2013
View article titled, Abstract 3370: Use of fine needle aspirate biopsy (FNAB) in evaluating drug responses in tumor models: Better data with less animal use? .
Journal Articles

Novel DNA binding mode and mechanism of action of XR5944, a potent clinical bisphenazine anticancer drug

Chandanamalie Punchihewa, Jixun Dai, Prakash Mistry, Danzhou Yang
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 353.
Published: 01 May 2005
View article titled, Novel DNA binding mode and mechanism of action of XR5944, a potent clinical bisphenazine anticancer drug
Journal Articles

Use of pheophorbide a, an ABCG2 specific substrate, to probe for ABCG2 expression and function

Robert W. Robey, Kenneth Steadman, Orsolya Polgar, Margaret Blayney, Prakash Mistry, Susan E. Bates
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 117.
Published: 01 April 2004
View article titled, Use of pheophorbide a, an ABCG2 specific substrate, to probe for ABCG2 expression and function
Journal Articles

Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition

Robert W. Robey, Kenneth Steadman, Orsolya Polgar, Kuniaki Morisaki, Margaret Blayney, Prakash Mistry, Susan E. Bates
Journal: Cancer Research
Cancer Res (2004) 64 (4): 1242–1246.
https://doi.org/10.1158/0008-5472.CAN-03-3298
Published: 18 February 2004
View article titled, Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition
Open the PDF for Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition in another window
Journal Articles

In Vitro and in Vivo Reversal of P-Glycoprotein-mediated Multidrug Resistance by a Novel Potent Modulator, XR9576

Prakash Mistry, Alistair J. Stewart, Wendy Dangerfield, Sade Okiji, Chris Liddle, Douglas Bootle, Jane A. Plumb, David Templeton, Peter Charlton
Journal: Cancer Research
Cancer Res (2001) 61 (2): 749–758.
Published: 01 January 2001
View article titled, <em>In Vitro and in Vivo</em> Reversal of P-Glycoprotein-mediated Multidrug Resistance by a Novel Potent Modulator, XR9576
Open the PDF for <em>In Vitro and in Vivo</em> Reversal of P-Glycoprotein-mediated Multidrug Resistance by a Novel Potent Modulator, XR9576 in another window
Journal Articles

Comparison of Cellular Accumulation and Cytotoxicity of Cisplatin with That of Tetraplatin and Amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in Human Ovarian Carcinoma Cell Lines

Prakash Mistry, Lloyd R. Kelland, Swee Y. Loh, George Abel, Barry A. Murrer, Ken R. Harrap
Journal: Cancer Research
Cancer Res (1992) 52 (22): 6188–6193.
Published: 01 November 1992
View article titled, Comparison of Cellular Accumulation and Cytotoxicity of Cisplatin with That of Tetraplatin and Amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in Human Ovarian Carcinoma Cell Lines
Open the PDF for Comparison of Cellular Accumulation and Cytotoxicity of Cisplatin with That of Tetraplatin and Amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in Human Ovarian Carcinoma Cell Lines in another window
Journal Articles

Sensitivity to Novel Platinum Compounds of Panels of Human Lung Cancer Cell Lines with Acquired and Inherent Resistance to Cisplatin

Peter R. Twentyman, Karen A. Wright, Prakash Mistry, Lloyd R. Kelland, Barry A. Murrer
Journal: Cancer Research
Cancer Res (1992) 52 (20): 5674–5680.
Published: 01 October 1992
View article titled, Sensitivity to Novel Platinum Compounds of Panels of Human Lung Cancer Cell Lines with Acquired and Inherent Resistance to Cisplatin
Open the PDF for Sensitivity to Novel Platinum Compounds of Panels of Human Lung Cancer Cell Lines with Acquired and Inherent Resistance to Cisplatin in another window
Journal Articles

Mechanism-related Circumvention of Acquired cis-Diamminedichloroplatinum(II) Resistance Using Two Pairs of Human Ovarian Carcinoma Cell Lines by Ammine/Amine Platinum(IV) Dicarboxylates

Lloyd R. Kelland, Prakash Mistry, George Abel, Swee Y. Loh, Ciaran F. O'Neill, Barry A. Murrer, Kenneth R. Harrap
Journal: Cancer Research
Cancer Res (1992) 52 (14): 3857–3864.
Published: 01 July 1992
View article titled, Mechanism-related Circumvention of Acquired <em>cis</em>-Diamminedichloroplatinum(II) Resistance Using Two Pairs of Human Ovarian Carcinoma Cell Lines by Ammine/Amine Platinum(IV) Dicarboxylates
Open the PDF for Mechanism-related Circumvention of Acquired <em>cis</em>-Diamminedichloroplatinum(II) Resistance Using Two Pairs of Human Ovarian Carcinoma Cell Lines by Ammine/Amine Platinum(IV) Dicarboxylates in another window
Journal Articles

Establishment and Characterization of an in Vitro Model of Acquired Resistance to Cisplatin in a Human Testicular Nonseminomatous Germ Cell Line

Lloyd R. Kelland, Prakash Mistry, George Abel, Frank Freidlos, Swee Y. Loh, John J. Roberts, Kenneth R. Harrap
Journal: Cancer Research
Cancer Res (1992) 52 (7): 1710–1716.
Published: 01 April 1992
View article titled, Establishment and Characterization of an <em>in Vitro</em> Model of Acquired Resistance to Cisplatin in a Human Testicular Nonseminomatous Germ Cell Line
Open the PDF for Establishment and Characterization of an <em>in Vitro</em> Model of Acquired Resistance to Cisplatin in a Human Testicular Nonseminomatous Germ Cell Line in another window
Journal Articles

Ammine/Amine Platinum(IV) Dicarboxylates: A Novel Class of Platinum Complex Exhibiting Selective Cytotoxicity to Intrinsically Cisplatin-resistant Human Ovarian Carcinoma Cell Lines

Lloyd R. Kelland, Barry A. Murrer, George Abel, Christen M. Giandomenico, Prakash Mistry, Kenneth R. Harrap
Journal: Cancer Research
Cancer Res (1992) 52 (4): 822–828.
Published: 01 February 1992
View article titled, Ammine/Amine Platinum(IV) Dicarboxylates: A Novel Class of Platinum Complex Exhibiting Selective Cytotoxicity to Intrinsically Cisplatin-resistant Human Ovarian Carcinoma Cell Lines
Open the PDF for Ammine/Amine Platinum(IV) Dicarboxylates: A Novel Class of Platinum Complex Exhibiting Selective Cytotoxicity to Intrinsically Cisplatin-resistant Human Ovarian Carcinoma Cell Lines in another window